Specifically, in the SUSTAIN‐6 trial, patients with type 2 diabetes and cardiovascular disease risk had a reduced rate of cardiovascular death, non‐fatal myocardial infarction and non‐fatal stroke when treated with the recently approved GLP‐1 mimetic semaglutide (Marso, Bain, et al., 2016). This evidence concerns the gene GCG and stroke disorder.